Aytu BioPharma (NASDAQ:AYTU) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why

Posted by Brian Himes on Aug 14th, 2026

Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.21 and traded as high as $2.40. Aytu BioPharma shares last traded at $2.30, with a volume of 43,533 shares changing hands.

Analyst Upgrades and Downgrades

AYTU has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Ascendiant Capital Markets raised their target price on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Aytu BioPharma presently has an average rating of “Hold” and a consensus price target of $10.75.

Read Our Latest Stock Analysis on AYTU

Aytu BioPharma Price Performance

The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $2.37. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The company has a market cap of $24.68 million, a P/E ratio of -0.50 and a beta of 0.25.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The firm had revenue of $12.41 million for the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. On average, equities analysts expect that Aytu BioPharma Inc. will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aytu BioPharma

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Aytu BioPharma in the 2nd quarter valued at $49,000. Rothschild Wealth LLC acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at $52,000. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma during the 3rd quarter worth about $58,000. XTX Topco Ltd bought a new position in shares of Aytu BioPharma during the 4th quarter worth about $67,000. Finally, DRW Securities LLC acquired a new stake in shares of Aytu BioPharma during the 4th quarter valued at about $76,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.